Bram joined Gimv in 2018. He has over 10 years of international venture capital experience, most recently at Merck Ventures in Amsterdam. Bram has a successful track record in life science investing and was instrumental in the formation, financing and/or exit of several start-ups across Europe and Israel, including arGEN-X (ARGX:EBR), Multiplicom (acquired by Agilent), Cartagenia (acquired by Agilent) and Q-Biologicals (acquired by Amatsigroup, now Eurofins). In addition to Topas Therapeutics, he is currently a board member of iSTAR Medical and Imcheck and an observer at Camel-IDs. Bram has a PhD in biotechnology from the University of Ghent (Belgium) and an executive MBA from Vlerick Business School (Belgium).